What the FDA labels say about taking them together
Iobenguane i 123 and labetalol
Iobenguane i 123's FDA label of January 10, 2024 names labetalol in its drug interactions section; the labetalol labels PlainMeds reads (2) do not name iobenguane i 123. The iobenguane i 123 label: “If the AdreView imaging information is essential for clinical care, consider the withdrawal of the following categories of medications if the withdrawal can be accomplished safely: antihypertensives that deplete …”
Check it at the source: the iobenguane i 123 FDA label on DailyMed (effective January 10, 2024); the labetalol FDA label on DailyMed (effective March 2, 2026, Zydus Pharmaceuticals USA Inc.).
What does the iobenguane i 123 label say about labetalol?
Iobenguane i 123 label, drug interactionsDRUG INTERACTIONS The following drugs have the potential to decrease the uptake of norepinephrine and cause false negative imaging results: antihypertensives that deplete norepinephrine stores or inhibit reuptake (e.g., reserpine, labetalol), antidepressants that inhibit norepinephrine transporter function (e.g., amitriptyline and derivatives, imipramine and derivatives, selective serotonin reuptake inhibitors), sympathomimetic amines (e.g., phenylephrine, phenylpropanolamine, pseudoephedrine and ephedrine), and cocaine.
Iobenguane i 123 label, warnings and precautionsIf the AdreView imaging information is essential for clinical care, consider the withdrawal of the following categories of medications if the withdrawal can be accomplished safely: antihypertensives that deplete norepinephrine stores or inhibit reuptake (e.g., reserpine, labetalol), antidepressants that inhibit norepinephrine transporter function (e.g., amitriptyline and derivatives, imipramine and derivatives, selective serotonin reuptake inhibitors), and sympathomimetic amines (e.g., phenylephrine, phenylpropanolamine, pseudoephedrine and ephedrine).
Source: FDA drug label (AdreView), Medi-Physics Inc., effective January 10, 2024 (SPL set c89d3ecc-4f4c-4566-8808-79152344194d), via openFDA; the full label on DailyMed
What does the labetalol label say about iobenguane i 123?
Labetalol's label (effective March 2, 2026) and its 1 other brand-application label do not name iobenguane i 123 in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Labetalol Hydrochloride), Zydus Pharmaceuticals USA Inc., effective March 2, 2026 (SPL set 5942a5a8-c3c1-4ecb-921e-9bc92393bdf8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Iobenguane i 123 | Labetalol | |
|---|---|---|
| Labeled for | n/a | High blood pressure |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.215 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once